Clinical Trials

Numerous clinical trials evaluate the therapeutic efficacy of fluticasone propionate across diverse inflammatory conditions, including asthma, chronic obstructive pulmonary disease, eosinophilic esophagitis, atopic dermatitis, and nasal allergy. These Phase 1 through Phase 4 investigations encompass completed, active, recruiting, terminated, and withdrawn studies. Research support stems from commercial sponsors such as GlaxoSmithKline, Teva Branded Pharmaceutical Products, and Eupraxia Pharmaceuticals, alongside academic institutions like M.D. Anderson Cancer Center.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05776927 RECRUITING
Asthma
Novartis Pharmaceuticals
 2026-08-04 PHASE3
NCT03742414 ACTIVE_NOT_RECRUITING
Eczema, Infantile; Eczema; Atopic Dermatitis Eczema; Atopic Dermatitis
Kari Nadeau, MD, PhD
 2021-06-30 PHASE2
NCT07582549 RECRUITING
Chronic Cough
Tampere University Hospital
 2025-12-22 PHASE3
NCT07664527 NOT_YET_RECRUITING
Asthma
University of Wisconsin, Madison
 2026-09 PHASE4
NCT05275686 RECRUITING
Eustachian Tube Dysfunction
Cedars-Sinai Medical Center
 2022-04-20 PHASE2
NCT07675252 NOT_YET_RECRUITING
Acute Wheezing Disorders in Infants Aged 0 to 24 Months
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
 2026-08-01 PHASE4
NCT07597473 RECRUITING
Allergic Rhinitis Due to Allergens
Viatris Inc.
 2026-05-08 PHASE4
NCT05535738 ACTIVE_NOT_RECRUITING
Skin Inflammation; Allergic Contact Dermatitis
Wei-Che Ko
 2022-11-15 PHASE2; PHASE3
NCT02476825 ACTIVE_NOT_RECRUITING
Healthy
University Hospitals, Leicester
 2016-01-20 PHASE4
NCT06052267 ACTIVE_NOT_RECRUITING
Asthma
Teva Branded Pharmaceutical Products R&D LLC
 2023-08-30 PHASE3
NCT06664619 RECRUITING
Asthma
Teva Branded Pharmaceutical Products R&D LLC
 2024-12-12 PHASE3
NCT07537439 ACTIVE_NOT_RECRUITING
Allergic Rhinitis (AR)
University of Medicine and Pharmacy at Ho Chi Minh City
 2026-03-01
NCT02630121 RECRUITING
Sleep Apnea; Chronic Nasal Congestion
University of South Florida
 2023-04-01 PHASE4
NCT07324707 RECRUITING
Bronchial Asthma
Anhui Palo Alto Pharmaceuticals, Inc.
 2025-10-15 PHASE2
NCT04171167 ACTIVE_NOT_RECRUITING
Chronic Rhinosinusitis (Diagnosis)
Tampere University Hospital
 2017-04-04
NCT07537751 COMPLETED
Atopic Dermatitis; Eczema
Noura Abdelmoneim Mohammed Elseessy
 2024-02-01
NCT06290102 COMPLETED
Asthma
Teva Branded Pharmaceutical Products R&D, Inc.
 2024-05-16 PHASE1
NCT05634746 COMPLETED
Eosinophilic Esophagitis
Ellodi Pharmaceuticals, LP
 2022-12-29 PHASE3
NCT05363202 UNKNOWN
Bronchial Asthma
Glenmark Pharmaceuticals Ltd. India
 2022-04-15 PHASE3
NCT06290102 Recruiting
Asthma
Teva Branded Pharmaceutical Products R&D Inc.
 2024-05-02 Phase 1
NCT06858423 COMPLETED
Nasal Allergy
Benha University
 2023-08-15 PHASE4
NCT07415278 ACTIVE_NOT_RECRUITING
Allergic Rhinitis
Pamukkale University
 2022-12-01 PHASE4
NCT05444543 COMPLETED
Eosinophilic Esophagitis
University Hospitals Cleveland Medical Center
 2021-11-17 PHASE4
NCT04655508 TERMINATED
Stem Cell Transplant Complications; Respiratory Disease; Bronchiolitis Obliterans
Assistance Publique - Hôpitaux de Paris
 2021-05-21 PHASE3
NCT06025214 UNKNOWN
Bioequivalence
Respirent Pharmaceuticals Co Ltd.
 2023-08-22 PHASE1
NCT05982990 UNKNOWN
Bioequivalence
Respirent Pharmaceuticals Co Ltd.
 2023-08-01 PHASE1
NCT05664061 UNKNOWN
Asthma
Respirent Pharmaceuticals Co Ltd.
 2023-01-30 PHASE3
NCT06180083 COMPLETED
Seasonal Allergic Rhinitis; Perennial Allergic Rhinitis
Humanis Saglık Anonim Sirketi
 2023-03-24 PHASE1
NCT02630121 Recruiting
Sleep Apnea|Chronic Nasal Congestion
University of South Florida
 2023-04 Phase 4
NCT05697003 UNKNOWN
Bioequivalence
Respirent Pharmaceuticals Co Ltd.
 2023-02-17 PHASE1
NCT05608681 Recruiting
Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Inc.
 2023-03-31 Phase 1|Phase 2
NCT05083312 COMPLETED
Eosinophilic Esophagitis
Ellodi Pharmaceuticals, LP
 2021-09-30 PHASE3
NCT04953741 UNKNOWN
Asthma in Children
Xijing Hospital
 2021-08-01 PHASE4
NCT05314621 COMPLETED
Allergic Conjunctivitis
Andover Research Eye Institute
 2021-12-31 PHASE4
NCT05397834 UNKNOWN
Asthma; Bioequivalence
Respirent Pharmaceuticals Co Ltd.
 2022-05-11 PHASE1
NCT04281108 COMPLETED
Eosinophilic Esophagitis
Ellodi Pharmaceuticals, LP
 2020-01-30 PHASE3
NCT04677959 COMPLETED
Asthma
Teva Branded Pharmaceutical Products R&D, Inc.
 2021-02-16 PHASE4
NCT05054322 UNKNOWN
Covid19
University of Medicine and Pharmacy at Ho Chi Minh City
 2021-09-22 PHASE2; PHASE3
NCT04652245 COMPLETED
Seasonal Allergic Rhinitis
MEDA Pharma GmbH & Co. KG
 2020-12-14 PHASE4
NCT05085587 UNKNOWN
Bioequivalence; Asthma
Respirent Pharmaceuticals Co Ltd.
 2021-10-01 PHASE1
NCT05021887 UNKNOWN
Asthma; Bioequivalence
Respirent Pharmaceuticals Co Ltd.
 2021-08-13 PHASE1
NCT04957927 UNKNOWN
Allergic Rhinitis
Usama Azhar
 2020-12-12 PHASE4
NCT04665895 COMPLETED
Asthma
Respirent Pharmaceuticals Co Ltd.
 2020-12-09 PHASE3
NCT06051786 COMPLETED
Allergic Rhinitis
Synmosa Biopharma Corp.
 2020-08-20 PHASE2
NCT04242368 WITHDRAWN
Chronic Rhinosinusitis (Diagnosis)
Stanford University
 2020-07-01 PHASE2; PHASE3
NCT04601324 WITHDRAWN
Allergic Rhinitis
St. Paul's Sinus Centre
 2020-12-15 PHASE4
NCT03879837 COMPLETED
Asthma
Actavis Inc.
 2019-03-25 PHASE3
NCT04271839 WITHDRAWN
Persistent Asthma
Mundipharma Pharmaceuticals S.L.
 2020-06-11 PHASE4
NCT04746040 UNKNOWN
Bioequivalence; Asthma
Respirent Pharmaceuticals Co Ltd.
 2021-01-18 PHASE1
NCT03199976 TERMINATED
Wheezy Bronchitis; Asthmatic Bronchitis; Wheezing; Obstruction Airway
Helsinki University Central Hospital
 2016-04-20 PHASE4
NCT04564456 COMPLETED
Bioequivalence
Respirent Pharmaceuticals Co Ltd.
 2020-09-22 PHASE1
NCT04546256 COMPLETED
Bioequivalence
Respirent Pharmaceuticals Co Ltd.
 2020-09-01 PHASE1
NCT04462822 COMPLETED
Bioequivalence
Respirent Pharmaceuticals Co Ltd.
 2020-08-24 PHASE1
NCT04466176 COMPLETED
Bioequivalence
Respirent Pharmaceuticals Co Ltd.
 2020-07-01 PHASE1
NCT04332978 COMPLETED
Perennial Allergic Rhinitis
Libbs Farmacêutica LTDA
 2014-07-04 PHASE3
NCT02883439 WITHDRAWN
Bioavailability Study
University Hospital, Ghent
 2016-08
NCT03394989 COMPLETED
Bronchial Asthma
Cipla Ltd.
 2018-10-17 PHASE3
NCT03756883 COMPLETED
Asthma
Actavis Inc.
 2018-12-03 PHASE3
NCT04124094 COMPLETED
Bioequivalence
Respirent Pharmaceuticals Co Ltd.
 2019-10-01 PHASE1
NCT02740543 COMPLETED
Asthma
NYU Langone Health
 2013-12 PHASE2
NCT03926026 COMPLETED
Blepharitis
Nicox Ophthalmics, Inc.
 2019-03-18 PHASE2
NCT04179461 COMPLETED
Asthma in Children
Children's Hospital Medical Center, Cincinnati
 2018-03-16 PHASE2
NCT03599791 COMPLETED
Allergic Rhinitis
MEDA Pharma GmbH & Co. KG
 2018-06-29 PHASE3
NCT03535870 COMPLETED
Asthma
West-Ward Pharmaceutical
 2018-04-26
NCT03676413 COMPLETED
Asthma
Respirent Pharmaceuticals Co Ltd.
 2018-10-02 PHASE3
NCT03975166 COMPLETED
Bioequivalence
Respirent Pharmaceuticals Co Ltd.
 2019-05-21 PHASE1
NCT03562923 UNKNOWN
Asthma
Amneal Ireland Limited
 2018-10 PHASE3
NCT02778867 COMPLETED
Eosinophilic Gastrointestinal Disorders (EGIDs); Eosinophilic Esophagitis (EoE)
Children's Hospital Medical Center, Cincinnati
 2016-05-20 PHASE2; PHASE3
NCT03894280 COMPLETED
Bioequivalence
Respirent Pharmaceuticals Co Ltd.
 2019-03-12 PHASE1
NCT03240575 COMPLETED
Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim
 2017-08-14 PHASE4
NCT02980133 COMPLETED
Asthma
Teva Branded Pharmaceutical Products R&D, Inc.
 2016-12-28 PHASE3
NCT03112577 COMPLETED
Asthma, Allergic
Regeneron Pharmaceuticals
 2017-06-15 PHASE1
NCT03591068 COMPLETED
Nasal Polyposis
Optinose US Inc.
 2018-06-07 PHASE3
NCT03207243 COMPLETED
Asthma
GlaxoSmithKline
 2017-09-14 PHASE2
NCT03820180 COMPLETED
Bioequivalence
Respirent Pharmaceuticals Co Ltd.
 2019-01-23 PHASE1
NCT03040596 TERMINATED
Vocal Fold Nodules
Joseph Dohar, MD
 2017-03-01 PHASE1
NCT02991859 COMPLETED
Asthma
GlaxoSmithKline
 2017-02-09 PHASE2
NCT03751202 COMPLETED
Bioequivalence
Respirent Pharmaceuticals Co Ltd.
 2018-11-20 PHASE1
NCT02554786 COMPLETED
Asthma
Novartis Pharmaceuticals
 2015-12-29 PHASE3
NCT02953106 TERMINATED
Asthma, Allergic; Rhinitis,Allergic; Allergy
University of Dundee
 2017-01-20 PHASE4
NCT02610816 COMPLETED
Eosinophilic Esophagitis; Eosinophilic Gastrointestinal Disorders (EGIDs)
Children's Hospital Medical Center, Cincinnati
 2016-03-21 PHASE2; PHASE3
NCT03443843 COMPLETED
Rhinitis, Allergic
Bayer
 2018-02-21 PHASE4
NCT03055988 COMPLETED
Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim
 2017-03-29 PHASE4
NCT02402465 COMPLETED
Allergic Rhinitis
University of Chicago
 2015-02 PHASE4
NCT01966692 COMPLETED
Asthma
University of Florida
 2016-11 PHASE1
NCT02573233 COMPLETED
Asthma
Sanofi
 2016-01-27 PHASE2
NCT02609126 COMPLETED
Osteoarthritis, Knee
Eupraxia Pharmaceuticals Inc.
 2016-04 PHASE1
NCT02757209 COMPLETED
Asthma; COPD
Consorzio Futuro in Ricerca
 2016-04
NCT02446418 COMPLETED
Asthma
GlaxoSmithKline
 2015-07-09 PHASE3
NCT02603393 COMPLETED
Chronic Obstructive Pulmonary Disease (COPD)
Novartis Pharmaceuticals
 2015-11-20 PHASE4
NCT03594565 COMPLETED
T1DM; Hypersensitivity
Assaf-Harofeh Medical Center
 2016-03 EARLY_PHASE1
NCT02024204 COMPLETED
Lung Diseases; Medication Compliance
NYU Langone Health
 2014-04-09
NCT03004131 COMPLETED
Seasonal Allergic Rhinitis
MEDA Pharma GmbH & Co. KG
 2017-01-07 PHASE4
NCT02730351 COMPLETED
Asthma
GlaxoSmithKline
 2016-05-25 PHASE4
NCT02301975 COMPLETED
Asthma
GlaxoSmithKline
 2015-03-01 PHASE3
NCT02496715 WITHDRAWN
Asthma
Actavis Inc.
 2015-09 PHASE3
NCT02693769 TERMINATED
ACOS (Fixed Airflow Obstruction and Elevated Eosinophils)
Mundipharma Research Limited
 2016-07 PHASE2; PHASE3
NCT02113436 COMPLETED
Asthma
GlaxoSmithKline
 2014-05-01 PHASE4
NCT02680561 COMPLETED
Asthma
Teva Branded Pharmaceutical Products R&D, Inc.
 2016-04 PHASE1
NCT02523820 COMPLETED
Stridor
Ramathibodi Hospital
 2015-01 PHASE3
NCT02195375 COMPLETED
Chronic Obstructive Pulmonary Disease
Mundipharma Research Limited
 2014-09 PHASE2; PHASE3
NCT01845025 TERMINATED
Persistent Asthma
Novartis Pharmaceuticals
 2013-05 PHASE4
NCT01946620 COMPLETED
Chronic Obstructive Pulmonary Disease
Mundipharma Research Limited
 2013-10 PHASE3
NCT01554488 TERMINATED
Asthma; Chronic Obstructive Pulmonary Disease; Obstructive Sleep Apnea
VA Office of Research and Development
 2013-03-12 PHASE4
NCT02665806 UNKNOWN
Chronic Rhinosinustis With Polyps
Tehran University of Medical Sciences
 2016-01 PHASE3
NCT01462344 COMPLETED
Asthma
GlaxoSmithKline
 2011-11-17 PHASE4
NCT02290717 WITHDRAWN
Vitiligo
Netherlands Institute for Pigment Disorders
 2015-05
NCT02649478 COMPLETED
Asthma
Roxane Laboratories
 2014-08
NCT02139644 COMPLETED
Asthma
Teva Branded Pharmaceutical Products R&D, Inc.
 2014-06 PHASE3
NCT02141854 COMPLETED
Asthma
Teva Branded Pharmaceutical Products R&D, Inc.
 2014-06 PHASE3
NCT01762800 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2013-02 PHASE4
NCT02094937 COMPLETED
Asthma
GlaxoSmithKline
 2014-03-27 PHASE3
NCT01622569 COMPLETED
Bilateral Nasal Polyposis
Optinose US Inc.
 2013-11-19 PHASE3
NCT01623310 COMPLETED
Nasal Polyps
Optinose US Inc.
 2013-09 PHASE3
NCT02175771 COMPLETED
Persistent Asthma
Teva Branded Pharmaceutical Products R&D, Inc.
 2014-07 PHASE3
NCT02245672 COMPLETED
Asthma
Mylan Pharma UK Ltd.
 2014-10 PHASE3
NCT02437604 COMPLETED
Asthma
Teva Branded Pharmaceutical Products R&D, Inc.
 2015-05 PHASE1
NCT01475721 COMPLETED
Asthma
GlaxoSmithKline
 2011-11-18 PHASE4
NCT02218762 WITHDRAWN
Asthma
GlaxoSmithKline
 2014-10 PHASE1
NCT02141633 COMPLETED
Smoking
University of Miami
 2013-04
NCT01624662 COMPLETED
Bilateral Nasal Polyposis
Optinose US Inc.
 2013-10-30 PHASE3
NCT02260492 COMPLETED
Asthma
Oriel Therapeutics
 2014-09 PHASE1
NCT01978145 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2013-11-14 PHASE3
NCT01606306 COMPLETED
Asthma; Wheezing
Milton S. Hershey Medical Center
 2013-02 PHASE3
NCT01623323 COMPLETED
Chronic Sinusitis With or Without Nasal Polyps
Optinose US Inc.
 2013-09 PHASE3
NCT02266927 COMPLETED
Mild to Moderate Asthma
Optinose US Inc.
 2014-09 PHASE1
NCT01915914 COMPLETED
Skin Diseases
GlaxoSmithKline
 2013-12-23 PHASE4
NCT02338362 COMPLETED
Ocular Hypertension; Glaucoma, Open-Angle
University Health Network, Toronto
 2014-09 PHASE4
NCT02230696 COMPLETED
Seasonal Allergic Rhinitis
Padagis LLC
 2014-08 PHASE3
NCT02249663 UNKNOWN
Seasonal Allergic Rhinitis
Teva Pharmaceuticals USA
 2014-08 PHASE3
NCT01978119 COMPLETED
Asthma
GlaxoSmithKline
 2013-11-06 PHASE3
NCT01969721 COMPLETED
Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim
 2013-10 PHASE3
NCT02232087 COMPLETED
Healthy
Kindeva Drug Delivery
 2014-07 PHASE1
NCT01563029 COMPLETED
Asthma
GlaxoSmithKline
 2012-03-28 PHASE2
NCT02466503 COMPLETED
Asthma; Chronic Obstructive Pulmonary Disease (COPD)
Intech Biopharm Ltd.
 2014-08 PHASE1
NCT01307462 COMPLETED
Bronchiolitis Obliterans
Stephanie Lee
 2011-06 PHASE2
NCT01908140 COMPLETED
Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca
 2013-09 PHASE3
NCT02466347 COMPLETED
Asthma; Chronic Obstructive Pulmonary Disease (COPD)
Intech Biopharm Ltd.
 2014-06 PHASE1
NCT02246920 TERMINATED
Seasonal Allergic Rhinitis
Teva Pharmaceuticals USA
 2014-03-01 PHASE3
NCT02094274 COMPLETED
Asthma
Almirall, S.A.
 2013-11 PHASE1
NCT01573767 COMPLETED
Asthma
GlaxoSmithKline
 2012-04 PHASE2
NCT01757015 WITHDRAWN
Chronic Obstructive Pulmonary Disease
Novartis Pharmaceuticals
 2013-04 PHASE3
NCT02045953 COMPLETED
Asthma
GlaxoSmithKline
 2014-01-29 PHASE1
NCT03444506 COMPLETED
Seasonal Allergic Rhinitis
Glenmark Pharmaceuticals Ltd. India
 2014-01-27 PHASE2
NCT01555138 COMPLETED
Chronic Obstructive Pulmonary Disease
Novartis Pharmaceuticals
 2012-02 PHASE4
NCT02279563 UNKNOWN
Seasonal Allergic Rhinitis
Apotex Inc.
 2013-12 PHASE2
NCT01915823 COMPLETED
Seasonal Allergic Rhinitis
Meda Pharmaceuticals
 2013-07 PHASE3
NCT01879410 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2013-06-13 PHASE3
NCT01687283 COMPLETED
Asthma
GlaxoSmithKline
 2012-09-27 PHASE3
NCT01751113 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2013-02 PHASE4
NCT02215122 COMPLETED
Asthma; COPD
Mylan Pharma UK Ltd.
 2013-10 PHASE1
NCT01794741 COMPLETED
Allergic Rhinitis
Meda Pharmaceuticals
 2013-02 PHASE3
NCT01516086 COMPLETED
Asthma
Dey
 2012-03 PHASE2
NCT01516073 COMPLETED
Asthma
Dey
 2012-03 PHASE2
NCT01817764 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2013-03-01 PHASE3
NCT01916226 COMPLETED
Rhinitis, Allergic, Perennial and Seasonal
GlaxoSmithKline
 2013-08-01 PHASE4
NCT01822899 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2013-04-04 PHASE3
NCT01890863 COMPLETED
Asthma
GlaxoSmithKline
 2013-08-05 PHASE1
NCT01856621 COMPLETED
Asthma
Orion Corporation, Orion Pharma
 2013-05 PHASE1
NCT01636076 COMPLETED
COPD
Novartis Pharmaceuticals
 2012-11 PHASE2
NCT01117116 COMPLETED
Asthma
National Jewish Health
 2010-03
NCT01795664 COMPLETED
Asthma
FLUIDDA nv
 2013-03 PHASE3
NCT01772147 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2013-01 PHASE3
NCT01772134 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2013-01-01 PHASE3
NCT01479621 COMPLETED
Asthma
Teva Branded Pharmaceutical Products R&D, Inc.
 2012-01 PHASE2
NCT00975195 COMPLETED
Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim
 2009-02 PHASE4
NCT01576718 COMPLETED
Asthma
Teva Branded Pharmaceutical Products R&D, Inc.
 2012-04 PHASE2
NCT01706328 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2012-10-15 PHASE3
NCT01687296 COMPLETED
Asthma
GlaxoSmithKline
 2012-11-12 PHASE3
NCT01772368 COMPLETED
Asthma
Teva Branded Pharmaceutical Products R&D, Inc.
 2013-01 PHASE2
NCT01766843 COMPLETED
Asthma
Orion Corporation, Orion Pharma
 2013-01 PHASE1
NCT01498653 COMPLETED
Asthma
GlaxoSmithKline
 2012-01 PHASE3
NCT01817790 COMPLETED
Allergic Rhinitis; Seasonal Allergic Rhinitis
GlaxoSmithKline
 2012-12 PHASE3
NCT01400906 COMPLETED
Asthma
GlaxoSmithKline
 2011-07-20 PHASE2
NCT01662778 COMPLETED
Asthma
Imperial College London
 2011-12 PHASE4
NCT01712451 COMPLETED
Abdominal Contour Defects
Neothetics, Inc
 2011-08 PHASE2
NCT01540708 COMPLETED
Asthma
GlaxoSmithKline
 2012-01-16 PHASE1
NCT01436110 COMPLETED
Asthma
GlaxoSmithKline
 2011-09 PHASE3
NCT01435902 WITHDRAWN
Asthma
GlaxoSmithKline
 2012-01 PHASE3
NCT01578278 COMPLETED
Seasonal Allergic Rhinitis
Bausch & Lomb Incorporated
 2011-12 PHASE2
NCT01564199 COMPLETED
Healthy Volunteer Study
Orion Corporation, Orion Pharma
 2012-04 PHASE1
NCT01321463 COMPLETED
Pulmonary Disease, Chronic Obstructive
Pfizer
 2011-05 PHASE2
NCT01110200 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2010-04-30 PHASE4
NCT01323621 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2011-03-18 PHASE3
NCT01159912 COMPLETED
Asthma
GlaxoSmithKline
 2010-06-30 PHASE3
NCT01400568 COMPLETED
Healthy
Fraunhofer-Institute of Toxicology and Experimental Medicine
 2011-08
NCT01364519 COMPLETED
Pulmonary Disease, Chronic Obstructive
Pfizer
 2011-07 PHASE1
NCT01772056 TERMINATED
Dermatitis, Atopic
Elena Rubio Gomis
 2009-12 PHASE3
NCT01397162 TERMINATED
Asthma
Boehringer Ingelheim
 2011-07-21 PHASE2
NCT01397201 TERMINATED
Asthma
Boehringer Ingelheim
 2011-07-01 PHASE2
NCT01323634 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2011-03-18 PHASE3
NCT01396278 TERMINATED
Asthma
Boehringer Ingelheim
 2011-07-01 PHASE2
NCT00995657 COMPLETED
Asthma
University of Dundee
 2009-10 PHASE4
NCT00395304 COMPLETED
Asthma
Milton S. Hershey Medical Center
 2007-03 PHASE3
NCT00426283 COMPLETED
Eosinophilic Esophagitis
Marc Rothenberg, MD
 2007-01 PHASE2
NCT01147744 COMPLETED
Asthma
GlaxoSmithKline
 2010-06-28 PHASE2
NCT01342913 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2011-02-01 PHASE3
NCT01248975 COMPLETED
Asthma
GlaxoSmithKline
 2010-12 PHASE2
NCT01134042 COMPLETED
Asthma
GlaxoSmithKline
 2010-06 PHASE3
NCT01439815 COMPLETED
Allergic Rhinitis; Allergic Conjunctivitis
ORA, Inc.
 2011-09 PHASE4
NCT01156792 COMPLETED
Asthma
GlaxoSmithKline
 2010-09 PHASE2
NCT01449799 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2011-07-13 PHASE1
NCT01253603 COMPLETED
Persistent Asthma
Novartis Pharmaceuticals
 2010-11 PHASE2
NCT01103349 COMPLETED
Asthma
Boehringer Ingelheim
 2010-04-20 PHASE2
NCT00845598 WITHDRAWN
Allergic Rhinitis
University of Dundee
 2010-08 PHASE4
NCT01424397 COMPLETED
Rhinitis
GlaxoSmithKline
 2011-04-14 PHASE2
NCT00692978 COMPLETED
Healthy; Asthma
Imperial College London
 2008-08 PHASE4
NCT01103934 COMPLETED
Seasonal Allergic Rhinitis
University of Chicago
 2010-06 PHASE4
NCT01147848 COMPLETED
Asthma
GlaxoSmithKline
 2010-06 PHASE3
NCT01494610 COMPLETED
Asthma
GlaxoSmithKline
 2010-10-25 PHASE1; PHASE2
NCT01124422 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2010-07-19 PHASE4
NCT01018186 COMPLETED
Asthma
GlaxoSmithKline
 2009-10-19 PHASE3
NCT00712335 COMPLETED
Asthmatic Smokers; Non-asthmatic Smokers
Inje University
 2007-02 PHASE4
NCT01092143 COMPLETED
Asthma
Boehringer Ingelheim
 2010-03-18 PHASE2
NCT01260753 COMPLETED
Seasonal Allergic Rhinitis
Palau Pharma S.L.U.
 2010-12 PHASE2
NCT01090024 COMPLETED
Asthma
Boehringer Ingelheim
 2010-03-01 PHASE2
NCT01243788 UNKNOWN
Chronic Obstructive Pulmonary Disease (COPD)
Fudan University
 2009-07 PHASE4
NCT00656916 TERMINATED
Bronchiolitis
M.D. Anderson Cancer Center
 2008-03 PHASE2
NCT01168310 COMPLETED
Chronic Obstructive Pulmonary Disease
Dey
 2010-08 PHASE2
NCT02136875 COMPLETED
COPD; Chronic Obstructive Pulmonary Disease
McGill University Health Centre/Research Institute of the McGill University Health Centre
 2008-07 PHASE4
NCT00843193 COMPLETED
Asthma
GlaxoSmithKline
 2008-12-09 PHASE2
NCT00984659 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2009-10-29 PHASE4
NCT00995800 COMPLETED
Asthma
Mundipharma Research Limited
 2009-10 PHASE2
NCT01526161 COMPLETED
Asthma
Professor Warren Lenney
 2009-04 PHASE4
NCT00706446 TERMINATED
Asthma
Brigham and Women's Hospital
 2008-06
NCT01007721 COMPLETED
Rhinitis, Allergic, Seasonal; Asthma
Boehringer Ingelheim
 2009-10 PHASE2
NCT00284856 COMPLETED
Asthma
Organon and Co
 2006-05 PHASE3
NCT01064726 COMPLETED
Allergic Rhinitis
Pfizer
 2009-10 PHASE1
NCT00857766 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2009-03 PHASE4
NCT00864812 COMPLETED
Chronic Obstructive Pulmonary Disease
The Korean Academy of Tuberculosis and Respiratory Diseases
 2009-03 PHASE4
NCT00497237 COMPLETED
Asthma
Chiesi Farmaceutici S.p.A.
 2007-04 PHASE3
NCT00784550 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2008-12 PHASE4
NCT00877539 COMPLETED
Asthma
Pfizer
 2009-06 PHASE1
NCT00927758 COMPLETED
Asthma
Sandoz
 2009-06 PHASE2
NCT00394355 COMPLETED
Asthma
Organon and Co
 2006-09 PHASE4
NCT00814216 COMPLETED
Asthma
Novartis
 2008-12 PHASE2
NCT00869596 COMPLETED
Airway Inflammation
Merck Sharp & Dohme LLC
 2009-03 PHASE1
NCT00562159 COMPLETED
Rhinoconjunctivitis; Rhinitis; Conjunctivitis; Allergy
ALK-Abelló A/S
 2007-11 PHASE3
NCT00527826 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2007-11 PHASE4
NCT00883168 COMPLETED
Seasonal Allergic Rhinitis
Meda Pharmaceuticals
 2009-04 PHASE3
NCT00487032 COMPLETED
Allergic Rhinitis; Tachyphylaxis; Rhinitis Medicamentosa
Brian J Lipworth
 2008-05 PHASE4
NCT00452699 COMPLETED
Asthma
GlaxoSmithKline
 2007-05 PHASE4
NCT00774761 COMPLETED
Chronic Obstructive Pulmonary Disease
Dey
 2008-11 PHASE2
NCT00318708 COMPLETED
Asthma
Milton S. Hershey Medical Center
 2006-06 PHASE3
NCT00452348 COMPLETED
Asthma
GlaxoSmithKline
 2007-05 PHASE4
NCT00633217 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2008-03 PHASE4
NCT00691665 COMPLETED
Seasonal Allergic Rhinitis
Alcon Research
 2008-05 PHASE4
NCT00546000 COMPLETED
Atopic Dermatitis
Fougera Pharmaceuticals Inc.
 2007-07 PHASE4
NCT00424008 COMPLETED
Asthma
Organon and Co
 2007-04 PHASE3
NCT00127166 COMPLETED
Exercise Induced Asthma
Organon and Co
 2005-12 PHASE3
NCT00716963 COMPLETED
Mild Intermittent Asthma
Hamilton Health Sciences Corporation
 2008-07 PHASE4
NCT00740792 COMPLETED
Seasonal Allergic Rhinitis
Meda Pharmaceuticals
 2008-08 PHASE3
NCT00603278 COMPLETED
Asthma
GlaxoSmithKline
 2007-12 PHASE2
NCT00995475 COMPLETED
COPD
University of Dundee
 2006-10 PHASE4
NCT00603382 COMPLETED
Asthma
GlaxoSmithKline
 2007-12-01 PHASE2
NCT00197106 COMPLETED
Asthma
GlaxoSmithKline
 2005-06 PHASE4
NCT00603746 COMPLETED
Asthma
GlaxoSmithKline
 2007-12-01 PHASE2
NCT00734292 COMPLETED
Mild to Moderate Asthma
SkyePharma AG
 2008-09 PHASE2
NCT00903227 COMPLETED
Asthma; Allergic Rhinitis
University of Dundee
 2006-12 PHASE4
NCT00503009 TERMINATED
Asthma
GlaxoSmithKline
 2007-10 PHASE4
NCT00517634 COMPLETED
Asthma
GlaxoSmithKline
 2007-08 PHASE4
NCT00119015 TERMINATED
Rhinitis, Allergic, Perennial
University of Chicago
 2005-07 PHASE4
NCT00651118 COMPLETED
Seasonal Allergic Rhinitis
Meda Pharmaceuticals
 2008-03 PHASE3
NCT00612820 COMPLETED
Rhinitis, Allergic, Seasonal
GlaxoSmithKline
 2008-01 PHASE2
NCT00557440 COMPLETED
Asthma
Novartis
 2007-11 PHASE2
NCT00393991 COMPLETED
Asthma
SkyePharma AG
 2006-07 PHASE3
NCT00393952 COMPLETED
Asthma
SkyePharma AG
 2006-06 PHASE3
NCT00540839 WITHDRAWN
Asthma, Bronchial
Organon and Co
 2007-11 PHASE3
NCT01365650 COMPLETED
Allergic Rhinitis
Egalet Ltd
 2007-12 PHASE1
NCT00660517 COMPLETED
Seasonal Allergic Rhinitis
Meda Pharmaceuticals
 2007-12 PHASE3
NCT00394199 COMPLETED
Asthma
SkyePharma AG
 2006-06 PHASE3
NCT00475813 COMPLETED
Asthma
Mundipharma Research Limited
 2007-03 PHASE3
NCT00848965 COMPLETED
Rhinitis, Allergic, Perennial; Allergic Rhinitis
GlaxoSmithKline
 2007-10 PHASE4
NCT00448435 COMPLETED
Bronchial Asthma
GlaxoSmithKline
 2007-04 PHASE3
NCT00476073 COMPLETED
Asthma Bronchiale
Mundipharma Research Limited
 2007-04 PHASE3
NCT00441441 COMPLETED
Asthma
GlaxoSmithKline
 2007-02 PHASE3
NCT00461500 COMPLETED
Asthma
GlaxoSmithKline
 2007-03 PHASE4
NCT00519636 COMPLETED
Rhinitis, Allergic, Perennial
GlaxoSmithKline
 2007-08 PHASE4
NCT00539006 COMPLETED
Rhinitis, Allergic, Perennial
GlaxoSmithKline
 2007-08 PHASE4
NCT00449046 COMPLETED
Bronchial Asthma
GlaxoSmithKline
 2007-03 PHASE3
NCT00296491 COMPLETED
Asthma
GlaxoSmithKline
 2005-09 PHASE4
NCT00355342 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2004-04-28 PHASE4
NCT00241631 COMPLETED
COPD
Imperial College London
 2006-04 PHASE2
NCT00296530 COMPLETED
Asthma
GlaxoSmithKline
 2005-09 PHASE4
NCT00291382 COMPLETED
Asthma
GlaxoSmithKline
 2005-11 PHASE4
NCT00346749 TERMINATED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2006-12 PHASE4
NCT00394121 COMPLETED
Asthma
SkyePharma AG
 2006-03 PHASE3
NCT00351143 COMPLETED
Asthma
GlaxoSmithKline
 2005-07-26 PHASE4
NCT00115492 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2004-12 PHASE4
NCT00403286 COMPLETED
Chronic Obstructive Pulmonary Disease
Dey
 2006-11 PHASE2
NCT01365611 COMPLETED
Healthy Subjects
Egalet Ltd
 2007-02 PHASE1
NCT00370097 COMPLETED
Asthma
GlaxoSmithKline
 2006-08-30 PHASE1
NCT00315744 COMPLETED
Asthma
GlaxoSmithKline
 2004-11-04 PHASE4
NCT00616538 COMPLETED
Atopic Dermatitis
Ceragenix Pharmaceuticals
 2006-12 PHASE4
NCT00102765 COMPLETED
Asthma
GlaxoSmithKline
 2004-11 PHASE4
NCT00385463 WITHDRAWN
Asthma; Seasonal Allergic Rhinitis
Creighton University
 2006-04
NCT00328718 COMPLETED
Asthma
GlaxoSmithKline
 2005-10 PHASE3
NCT00358358 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2006-03 PHASE4
NCT00404586 COMPLETED
Rhinitis, Allergic, Perennial
GlaxoSmithKline
 2006-09-11 PHASE1
NCT00102882 COMPLETED
Asthma
GlaxoSmithKline
 2004-10 PHASE4
NCT00398476 COMPLETED
Rhinitis, Allergic, Perennial
GlaxoSmithKline
 2006-12-01 PHASE3
NCT00144911 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2004-10 PHASE4
NCT00400998 COMPLETED
Allergic Rhinitis; Rhinitis, Allergic, Seasonal
Research Consult GmbH
 2006-03 PHASE2
NCT00266578 COMPLETED
Eosinophilic Esophagitis
Marc Rothenberg
 2002-10 PHASE3
NCT00353873 COMPLETED
Asthma
GlaxoSmithKline
 2005-11-18 PHASE4
NCT00269087 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2005-01-28 PHASE3
NCT00071552 TERMINATED
Asthma
Teva Branded Pharmaceutical Products R&D, Inc.
 2004-01-31 PHASE4
NCT00118716 COMPLETED
Bronchospasm; Activity/Exercise Induced Bronchospasm
GlaxoSmithKline
 2003-12-23 PHASE4
NCT00549146 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2003-11 PHASE3
NCT00361959 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2003-06 PHASE4
NCT00163423 COMPLETED
Asthma
AstraZeneca
 2004-11 PHASE3
NCT00169546 COMPLETED
Asthma
GlaxoSmithKline
 2003-01 PHASE4
NCT00163371 COMPLETED
Asthma
AstraZeneca
 2005-09 PHASE3
NCT00118690 COMPLETED
Bronchospasm; Activity/Exercise Induced Bronchospasm
GlaxoSmithKline
 2003-12 PHASE4
NCT00268216 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2000-09 PHASE3
NCT00163462 COMPLETED
Asthma
AstraZeneca
 2004-10 PHASE3
NCT00783224 COMPLETED
Perennial Allergic Rhinitis
Organon and Co
 2005-09 PHASE3
NCT00163358 COMPLETED
Asthma
AstraZeneca
 2003-09 PHASE3
NCT00480649 COMPLETED
Asthma
GlaxoSmithKline
 2004-01 PHASE4
NCT00269126 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2005-02 PHASE3
NCT00163488 COMPLETED
Perennial Allergic Rhinitis; Allergic Rhinitis; Hay Fever
AstraZeneca
 2005-01 PHASE3
NCT00400855 COMPLETED
Asthma
GlaxoSmithKline
 2005-01 PHASE2
NCT00369993 COMPLETED
Asthma
GlaxoSmithKline
 2005-03 PHASE2
NCT00364442 COMPLETED
Asthma
GlaxoSmithKline
 2005-01-28 PHASE1
NCT00363740 COMPLETED
Rhinitis, Allergic, Seasonal
GlaxoSmithKline
 2005-02-19 PHASE3
NCT00830102 COMPLETED
Asthma
SkyePharma AG
 2004-10 PHASE2
NCT00163410 COMPLETED
Asthma
AstraZeneca
 2003-04 PHASE3
NCT00920543 COMPLETED
Asthma
GlaxoSmithKline
 2003-02 PHASE4
NCT01324362 COMPLETED
Asthma
GlaxoSmithKline
 2003-01 PHASE4
NCT00239421 COMPLETED
Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim
 2003-11 PHASE4
NCT00479739 COMPLETED
Asthma
GlaxoSmithKline
 2002-11 PHASE4
NCT00453778 COMPLETED
Asthma; Mild Asthma
GlaxoSmithKline
 2002-11 PHASE4
NCT00370591 COMPLETED
Asthma
GlaxoSmithKline
 2002-12 PHASE4
NCT00920959 COMPLETED
Asthma
GlaxoSmithKline
 2001-11 PHASE3
NCT00641680 COMPLETED
Seasonal Allergic Rhinitis
AstraZeneca
 2003-04 PHASE3
NCT00606242 COMPLETED
Asthma
University of California, San Francisco
 2000-01 PHASE4
NCT00489346 COMPLETED
Asthma, Bronchial
Organon and Co
 2001-10 PHASE3
NCT03882047 COMPLETED
Rhinitis, Allergic, Seasonal
Organon and Co
 1994-08-11 PHASE3
NCT00307970 COMPLETED
Asthma
University of Florida
 2003-04 PHASE4
NCT00280358 COMPLETED
Healthy
Dey
 PHASE1
NCT00158834 COMPLETED
Asthma
GlaxoSmithKline
 1999-11 PHASE3
NCT00409630 WITHDRAWN
Asthma
University of Kansas
NCT00163319 COMPLETED
Asthma
AstraZeneca
 2004-11 PHASE3
NCT00184977 COMPLETED
Pulmonary Disease, Chronic Obstructive; Lung Diseases, Obstructive; Bronchitis, Chronic
Radboud University Medical Center
 1998-12 PHASE4
NCT00755066 COMPLETED
Seasonal Allergic Rhinitis
Medical University of Vienna
NCT00348361 COMPLETED
Allergic Rhinitis
GlaxoSmithKline
 2005-04 PHASE1
NCT00407264 COMPLETED
Bronchogenic Carcinoma
Amsterdam UMC, location VUmc
 2002-02 PHASE2
NCT00394368 COMPLETED
Bronchial Asthma
Chiesi Farmaceutici S.p.A.
 2004-11 PHASE3
NCT00273026 TERMINATED
Asthma
GlaxoSmithKline
 2004-11-08 PHASE4
NCT00400608 COMPLETED
Asthma
GlaxoSmithKline
 2006-10 PHASE4
NCT00411372 WITHDRAWN
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2006-11 PHASE3
NCT00268177 COMPLETED
Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
 2002-10 PHASE3
NCT00846326 WITHDRAWN
Allergic Rhinitis; Tachyphylaxis; Rhinitis Medicamentosa
Brian J Lipworth
 PHASE4
NCT00163332 COMPLETED
Asthma
AstraZeneca
 2003-03 PHASE3

(data from https://clinicaltrials.gov, updated on 2026-08-26)

Check the Fluticasone propionate product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Fluticasone propionate selectively binds to the intracellular glucocorticoid receptor with high affinity, promoting receptor translocation to the cell nucleus to repress pro-inflammatory gene transcription and suppress inflammatory signaling cascades. This molecular inhibition decreases cytokine production and mucosal immune cell recruitment, effectively relieving airway hyperresponsiveness and tissue inflammation in conditions such as asthma, chronic obstructive pulmonary disease, and eosinophilic esophagitis.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.